Leqvio

Chemical Nameinclisiran
Dosage FormInjection (subcutaneous; 284 mg/1.5 mL)
Drug ClassSmall interfering RNA directed to proprotein convertase subtilisin kexin type 9 mRNA
SystemCardiovascular
CompanyNovartis
Approval Year2021

Indication

  • Indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C).
Last updated on 12/7/2022

More on this drug: Clinical Trials

Document TitleYearSource
Leqvio (inclisiran) Prescribing Information.2021Novartis Pharmaceuticals Corporation, East Hanover, NJ